AU2018248324B2 - Proteins for the treatment of epithelial barrier function disorders - Google Patents

Proteins for the treatment of epithelial barrier function disorders Download PDF

Info

Publication number
AU2018248324B2
AU2018248324B2 AU2018248324A AU2018248324A AU2018248324B2 AU 2018248324 B2 AU2018248324 B2 AU 2018248324B2 AU 2018248324 A AU2018248324 A AU 2018248324A AU 2018248324 A AU2018248324 A AU 2018248324A AU 2018248324 B2 AU2018248324 B2 AU 2018248324B2
Authority
AU
Australia
Prior art keywords
seq
amino acid
protein
acid sequence
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018248324A
Other languages
English (en)
Other versions
AU2018248324A1 (en
Inventor
Stefanie BANAS
Karim DABBAGH
Todd Zachary DESANTIS
Andrew Whitman GOODYEAR
Tarunmeet GUJRAL
Andrew Wonhee HAN
Ye Jin
Toshihiko Takeuchi
Michi Izumi WILLCOXON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genevive Inc
Original Assignee
Genevive Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genevive Inc filed Critical Genevive Inc
Publication of AU2018248324A1 publication Critical patent/AU2018248324A1/en
Application granted granted Critical
Publication of AU2018248324B2 publication Critical patent/AU2018248324B2/en
Priority to AU2023202844A priority Critical patent/AU2023202844A1/en
Assigned to GENEVIVE, INC. reassignment GENEVIVE, INC. Request for Assignment Assignors: SECOND GENOME, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Prostheses (AREA)
AU2018248324A 2017-04-07 2018-04-06 Proteins for the treatment of epithelial barrier function disorders Active AU2018248324B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023202844A AU2023202844A1 (en) 2017-04-07 2023-05-08 Proteins for the treatment of epithelial barrier function disorders

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762482963P 2017-04-07 2017-04-07
US62/482,963 2017-04-07
US201762607706P 2017-12-19 2017-12-19
US62/607,706 2017-12-19
US201762611334P 2017-12-28 2017-12-28
US62/611,334 2017-12-28
PCT/US2018/026447 WO2018187682A1 (en) 2017-04-07 2018-04-06 Proteins for the treatment of epithelial barrier function disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023202844A Division AU2023202844A1 (en) 2017-04-07 2023-05-08 Proteins for the treatment of epithelial barrier function disorders

Publications (2)

Publication Number Publication Date
AU2018248324A1 AU2018248324A1 (en) 2019-10-31
AU2018248324B2 true AU2018248324B2 (en) 2023-02-09

Family

ID=63710147

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018248324A Active AU2018248324B2 (en) 2017-04-07 2018-04-06 Proteins for the treatment of epithelial barrier function disorders
AU2023202844A Abandoned AU2023202844A1 (en) 2017-04-07 2023-05-08 Proteins for the treatment of epithelial barrier function disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023202844A Abandoned AU2023202844A1 (en) 2017-04-07 2023-05-08 Proteins for the treatment of epithelial barrier function disorders

Country Status (12)

Country Link
US (3) US11207376B2 (enExample)
EP (1) EP3606542B1 (enExample)
JP (2) JP7789303B2 (enExample)
KR (2) KR20200003821A (enExample)
CN (1) CN110769844B (enExample)
AU (2) AU2018248324B2 (enExample)
CA (1) CA3059354A1 (enExample)
IL (1) IL269853A (enExample)
MX (2) MX393998B (enExample)
SG (1) SG11201909334TA (enExample)
TW (1) TWI797116B (enExample)
WO (1) WO2018187682A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11207376B2 (en) 2017-04-07 2021-12-28 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
US11666627B2 (en) 2017-04-07 2023-06-06 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
WO2019195859A1 (en) * 2018-04-06 2019-10-10 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
WO2020077010A1 (en) * 2018-10-09 2020-04-16 Second Genome, Inc. Lactococcus lactis expression system for delivering proteins efficacious for the treatment of epithelial barrier function disorders
JP2022544992A (ja) * 2019-08-21 2022-10-24 アストラゼネカ・コラボレイション・ベンチャーズ・リミテッド・ライアビリティ・カンパニー クローン病を治療するためのブラジクマブの使用
WO2021139766A1 (en) * 2020-01-10 2021-07-15 Huang Chih Hung Peptide interacting with toll-like receptor 2 and the composition comprising the same
CN113773364B (zh) * 2021-08-25 2023-04-28 无锡市儿童医院 小分子肽及其制备方法和应用
EP4611774A2 (en) * 2022-11-04 2025-09-10 MiNK Therapeutics, Inc. B-cell maturation antigen (bcma) chimeric antigen receptor invariant natural killer t cells and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279177A1 (en) * 2011-10-07 2016-09-29 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
WO2016203221A1 (en) * 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5856457A (en) 1991-03-29 1999-01-05 Genentech, Inc. Nucleic acids encoding a human IL-8 receptor
US6734289B2 (en) 2001-03-29 2004-05-11 The University Of Chicago Gastrokines and derived peptides including inhibitors
US20060189526A1 (en) 2002-04-24 2006-08-24 Podolsky Daniel K Compositions containing an intestinal trefoil peptide and a mucoadhesive
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
ES2568938T3 (es) 2009-04-28 2016-05-05 Vanderbilt University Composiciones y procedimientos de tratamiento de trastornos que implican apoptosis de células epiteliales
JP2014093482A (ja) 2012-11-06 2014-05-19 Toshiba Corp 固体撮像装置の製造方法および固体撮像装置
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2015014973A2 (en) * 2013-07-31 2015-02-05 Institut National De La Recherche Agronomique Use of specific glycoside phosphorylases for the implementation of phosphorolysis or reverse phosphorolysis reactions
US11666627B2 (en) * 2017-04-07 2023-06-06 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
US11207376B2 (en) 2017-04-07 2021-12-28 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
US11174293B2 (en) 2017-06-02 2021-11-16 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
WO2019195859A1 (en) 2018-04-06 2019-10-10 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279177A1 (en) * 2011-10-07 2016-09-29 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
WO2016203221A1 (en) * 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains

Also Published As

Publication number Publication date
IL269853A (en) 2019-11-28
MX393998B (es) 2025-03-24
KR20230144097A (ko) 2023-10-13
US20240066095A1 (en) 2024-02-29
KR20200003821A (ko) 2020-01-10
US20180289770A1 (en) 2018-10-11
EP3606542B1 (en) 2026-06-10
US10251933B2 (en) 2019-04-09
US12661383B2 (en) 2026-06-23
JP2024037834A (ja) 2024-03-19
CN110769844A (zh) 2020-02-07
CN110769844B (zh) 2025-01-21
WO2018187682A1 (en) 2018-10-11
TWI797116B (zh) 2023-04-01
SG11201909334TA (en) 2019-11-28
AU2023202844A1 (en) 2023-07-06
TW201841649A (zh) 2018-12-01
US11207376B2 (en) 2021-12-28
MX2019012051A (es) 2020-02-12
MX2022008842A (es) 2022-08-02
JP7789303B2 (ja) 2025-12-22
EP3606542A4 (en) 2021-01-20
US20200148728A1 (en) 2020-05-14
CA3059354A1 (en) 2018-10-11
EP3606542A1 (en) 2020-02-12
AU2018248324A1 (en) 2019-10-31
JP2020516615A (ja) 2020-06-11
KR102903277B1 (ko) 2025-12-23

Similar Documents

Publication Publication Date Title
US20240066095A1 (en) Proteins for the treatment of epithelial barrier function disorders
US12168677B2 (en) Proteins for the treatment of epithelial barrier function disorders
US11505583B2 (en) Proteins for the treatment of epithelial barrier function disorders
US12186364B2 (en) Proteins for the treatment of epithelial barrier function disorders
US20210380994A1 (en) Lactococcus lactis expression system for delivering proteins efficacious for the treatment of epithelial barrier function disorders
US11666627B2 (en) Proteins for the treatment of epithelial barrier function disorders
US12371456B2 (en) Proteins for the treatment of epithelial barrier function disorders
WO2019213105A1 (en) Methods and compositions involving plantaricin ef (plnef)
WO2021205150A1 (en) An enzyme
WO2012156811A2 (en) Compositions useful for the treatment of inflammatory disease or disorders
CN121698982A (zh) 一种用于诱导线粒体钙超载的分离的多肽及其应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: GENEVIVE, INC.

Free format text: FORMER OWNER(S): SECOND GENOME, INC.